The German reimbursement authority renewed payment coding for Medovex’s DenerveX™ technology for the treatment of the facet joint syndrome for 2017.
While DenerveX is not yet CE-Marked or FDA-cleared, leadership expects that the renewal will be a significant driver for European launch preparation. The company has already confirmed first distributor partnerships.
The German reimbursement authority renewed payment coding for Medovex's DenerveX™ technology for the treatment of the facet joint syndrome for 2017.
While DenerveX is not yet CE-Marked or FDA-cleared, leadership expects that the renewal will be a significant driver for European launch preparation. The...
The German reimbursement authority renewed payment coding for Medovex’s DenerveX™ technology for the treatment of the facet joint syndrome for 2017.
While DenerveX is not yet CE-Marked or FDA-cleared, leadership expects that the renewal will be a significant driver for European launch preparation. The company has already confirmed first distributor partnerships.
Copy to clipboard 
